New hope for Tough-to-Treat depression: experimental Add-On drug enters final testing

NCT ID NCT06786624

Recruiting now Disease control Sponsor: Neurocrine Biosciences Source: ClinicalTrials.gov ↗

Summary

This study is testing whether adding an experimental drug called NBI-1065845 to a person's current antidepressant medication helps reduce depression symptoms more effectively. It involves 200 adults with moderate-to-severe depression who haven't gotten enough relief from their current antidepressant alone. Participants will continue taking their regular antidepressant while receiving either the experimental add-on drug or a placebo for 8 weeks to compare results.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Neurocrine Clinical Site
RECRUITING

Little Rock, Arkansas, 72204, United States
Neurocrine Clinical Site
COMPLETED

Garden Grove, California, 92844, United States
Neurocrine Clinical Site
RECRUITING

Orange, California, 92866, United States
Neurocrine Clinical Site
RECRUITING

Pico Rivera, California, 90660, United States
Neurocrine Clinical Site
RECRUITING

San Diego, California, 92103, United States
Neurocrine Clinical Site
RECRUITING

Upland, California, 91786, United States
Neurocrine Clinical Site
RECRUITING

Hollywood, Florida, 33024, United States
Neurocrine Clinical Site
RECRUITING

Maitland, Florida, 32751, United States
Neurocrine Clinical Site
RECRUITING

Boston, Massachusetts, 02116, United States
Neurocrine Clinical Site
SUSPENDED

Watertown, Massachusetts, 02472, United States
Neurocrine Clinical Site
RECRUITING

Mount Kisco, New York, 10549, United States
Neurocrine Clinical Site
RECRUITING

Avon Lake, Ohio, 44012, United States
Neurocrine Clinical Site
COMPLETED

Westlake, Ohio, 44145, United States
Neurocrine Clinical Site
RECRUITING

Dallas, Texas, 75251, United States
Neurocrine Clinical Site
RECRUITING

Houston, Texas, 77030, United States
Neurocrine Clinical Site
WITHDRAWN

Richmond, Texas, 77407, United States
Neurocrine Clinical Site
SUSPENDED

The Woodlands, Texas, 77381, United States
Neurocrine Clinical Site
RECRUITING

Everett, Washington, 98201, United States

Conditions

Explore the condition pages connected to this study.

MAJOR DEPRESSIVE DISORDER